Shingles vaccine to prevent heart problems in adults at risk
Part of Heart & circulation clinical trials.
This study tests whether a shingles vaccine can reduce the chance of serious heart problems in adults 50 and older who already have heart or blood vessel disease, or who have at least two risk factors like high blood pressure or diabetes. If it works, this vaccine could become a new way to protect your heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with heart disease, narrowed blood vessels, or had a stroke, OR you have at least two of these risk factors: high blood pressure, high cholesterol, diabetes, or smoking.
- You are under a doctor's care for your heart condition or risk factors and taking recommended medications.
- You have not had a heart attack, stroke, or hospital stay for chest pain in the last 3 months.
- You have not had the shingles vaccine before and are not planning to get it during the study.
- You are not taking medicines that weaken the immune system (like long-term steroids) and do not have a condition that suppresses immunity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing two different vaccines—one for shingles and one for RSV—to see if they can slow down build-up of plaque in the heart arteries. If you are 50 or older and have heart disease risk factors, this study may help researchers learn if these vaccines offer extra benefits.
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This study tests a new shingles vaccine (called an mRNA vaccine) given as a shot. It aims to prevent shingles in adults aged 40 and above. If you qualify, you may receive the vaccine or a placebo, and your health will be monitored for a period of time.
Hear when a new Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.